Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)

#1455

Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.

Aim(s): The aim of this study was to examine the expression and potential clinical importance of mutated p53 in GEP-NEC

Materials and methods: Tumor tissues from 125 GEP-NEC patients (median age 64 years) treated with platinum-based chemotherapy were collected from Nordic centers and clinical data from the Nordic NEC register. All specimens were immunostained for p53 using commercially available antibodies. Kaplan Meir and cox regression were used to assess overall survival (OS

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Ali A, Grönberg M, Federspiel B, Hjortland G, Ladekarl M,

Keywords: Neuroendocrine Carcinoma, mutation, p53, overall survival,